Author:
Nakanishi Yukako,Kitajima Kazuhiro,Yamada Yusuke,Hashimoto Takahiko,Suzuki Toru,Go Shuken,Kanematsu Akihiro,Nojima Michio,Yamakado Koichiro,Yamamoto Shingo
Publisher
Springer Science and Business Media LLC
Subject
Radiology Nuclear Medicine and imaging,General Medicine
Reference25 articles.
1. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. Guidelines on renal cell carcinoma. Eur Urol. 2015;67:913–24.
2. Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, et al. ESMO Guidelines Working Group. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):49–56.
3. Smaldone MC, Chen DY, Yu JQ, Plimack ER. Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395–407.
4. Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, et al. FDG and FLT-PET for early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer Imaging. 2015;15:15.
5. Oyama N, Takahara N, Hasegawa Y, Tanase K, Miwa Y, Akino H, et al. Assessment of therapeutic effect of sunitinib by 11C-Acetate PET compared with FDG PET imaging in a patient with metastatic renal cell carcinoma. Nucl Med Mol Imaging. 2011;45:217–19.
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献